Cargando…
Pien Tze Huang regulates phosphorylation of metabolic enzymes in mice of hepatocellular carcinoma
The Chinese medicine formula Pien Tze Huang (PZH) has been applied to the treatment of various diseases, the reported anti-tumor mechanisms included regulation of inflammation-associated cytokine secretion and cancer growth pathways. However, the potential influence of PZH on tumor metabolism remain...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894829/ https://www.ncbi.nlm.nih.gov/pubmed/36732657 http://dx.doi.org/10.1038/s41598-023-29116-8 |
_version_ | 1784881816171184128 |
---|---|
author | Lin, Jinxia Wang, Shicong Lan, Wenliang Ji, Ming Li, Mei |
author_facet | Lin, Jinxia Wang, Shicong Lan, Wenliang Ji, Ming Li, Mei |
author_sort | Lin, Jinxia |
collection | PubMed |
description | The Chinese medicine formula Pien Tze Huang (PZH) has been applied to the treatment of various diseases, the reported anti-tumor mechanisms included regulation of inflammation-associated cytokine secretion and cancer growth pathways. However, the potential influence of PZH on tumor metabolism remains unclear. This study aimed to investigate the global effect of PZH on hepatocellular carcinoma (HCC) compared with the anti-tumor agent sorafenib based on tandem mass tag (TMT) label proteomic and phosphoproteomic analysis in addition to parallel reaction monitoring (PRM) verification. It was observed that PZH could inhibit tumor weight by 59–69% in different concentrations. TMT proteomic studies indicated that fructose/mannose metabolism and glucagon signaling pathway in PZH group, and arachidonic acid metabolism and PPAR signaling pathway in sorafenib group, were significantly enriched, while glycolysis/gluconeogenesis pathway was found to be enriched remarkably both in PZH and sorafenib groups in TMT phosphoproteomic study. PRM verification further indicated that both PZH and sorafenib could down-regulate phosphorylations of the glycolytic enzymes phosphofructokinases 1, fructose-bisphosphate Aldolase A, phosphoglycerate mutase 2 and lactate dehydrogenase A chain, while phosphorylations of long chain fatty acid CoA ligase in fatty acid activation and acetyl-coenzyme A synthetase in glycolysis were significantly inhibited by PZH and sorafenib, respectively. This study proposed that PZH shared a similar anti-tumor mechanism of metabolic regulation to sorafenib, but differed in the regulation of some metabolic nodes. This is the first time to uncover the relationship between the anti-tumor effect of PZH and metabolic related enzymes, which distinguished from the known mechanisms of PZH. These data provided the potential molecular basis for PZH acting as a therapeutic drug for HCC, and offered cues of manipulation on Warburg effect under the treatment of PZH. |
format | Online Article Text |
id | pubmed-9894829 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-98948292023-02-04 Pien Tze Huang regulates phosphorylation of metabolic enzymes in mice of hepatocellular carcinoma Lin, Jinxia Wang, Shicong Lan, Wenliang Ji, Ming Li, Mei Sci Rep Article The Chinese medicine formula Pien Tze Huang (PZH) has been applied to the treatment of various diseases, the reported anti-tumor mechanisms included regulation of inflammation-associated cytokine secretion and cancer growth pathways. However, the potential influence of PZH on tumor metabolism remains unclear. This study aimed to investigate the global effect of PZH on hepatocellular carcinoma (HCC) compared with the anti-tumor agent sorafenib based on tandem mass tag (TMT) label proteomic and phosphoproteomic analysis in addition to parallel reaction monitoring (PRM) verification. It was observed that PZH could inhibit tumor weight by 59–69% in different concentrations. TMT proteomic studies indicated that fructose/mannose metabolism and glucagon signaling pathway in PZH group, and arachidonic acid metabolism and PPAR signaling pathway in sorafenib group, were significantly enriched, while glycolysis/gluconeogenesis pathway was found to be enriched remarkably both in PZH and sorafenib groups in TMT phosphoproteomic study. PRM verification further indicated that both PZH and sorafenib could down-regulate phosphorylations of the glycolytic enzymes phosphofructokinases 1, fructose-bisphosphate Aldolase A, phosphoglycerate mutase 2 and lactate dehydrogenase A chain, while phosphorylations of long chain fatty acid CoA ligase in fatty acid activation and acetyl-coenzyme A synthetase in glycolysis were significantly inhibited by PZH and sorafenib, respectively. This study proposed that PZH shared a similar anti-tumor mechanism of metabolic regulation to sorafenib, but differed in the regulation of some metabolic nodes. This is the first time to uncover the relationship between the anti-tumor effect of PZH and metabolic related enzymes, which distinguished from the known mechanisms of PZH. These data provided the potential molecular basis for PZH acting as a therapeutic drug for HCC, and offered cues of manipulation on Warburg effect under the treatment of PZH. Nature Publishing Group UK 2023-02-02 /pmc/articles/PMC9894829/ /pubmed/36732657 http://dx.doi.org/10.1038/s41598-023-29116-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Lin, Jinxia Wang, Shicong Lan, Wenliang Ji, Ming Li, Mei Pien Tze Huang regulates phosphorylation of metabolic enzymes in mice of hepatocellular carcinoma |
title | Pien Tze Huang regulates phosphorylation of metabolic enzymes in mice of hepatocellular carcinoma |
title_full | Pien Tze Huang regulates phosphorylation of metabolic enzymes in mice of hepatocellular carcinoma |
title_fullStr | Pien Tze Huang regulates phosphorylation of metabolic enzymes in mice of hepatocellular carcinoma |
title_full_unstemmed | Pien Tze Huang regulates phosphorylation of metabolic enzymes in mice of hepatocellular carcinoma |
title_short | Pien Tze Huang regulates phosphorylation of metabolic enzymes in mice of hepatocellular carcinoma |
title_sort | pien tze huang regulates phosphorylation of metabolic enzymes in mice of hepatocellular carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894829/ https://www.ncbi.nlm.nih.gov/pubmed/36732657 http://dx.doi.org/10.1038/s41598-023-29116-8 |
work_keys_str_mv | AT linjinxia pientzehuangregulatesphosphorylationofmetabolicenzymesinmiceofhepatocellularcarcinoma AT wangshicong pientzehuangregulatesphosphorylationofmetabolicenzymesinmiceofhepatocellularcarcinoma AT lanwenliang pientzehuangregulatesphosphorylationofmetabolicenzymesinmiceofhepatocellularcarcinoma AT jiming pientzehuangregulatesphosphorylationofmetabolicenzymesinmiceofhepatocellularcarcinoma AT limei pientzehuangregulatesphosphorylationofmetabolicenzymesinmiceofhepatocellularcarcinoma |